Key Highlights

● Verdict: A federal Jury found Eli Lilly breached the implied covenant of good faith and fair dealing in its rezpegaldesleukin license agreement with Nektar.

● Damages: The jury awarded Nektar $90 million in damages, reached September 24, 2026, with interest to be determined separately by the court.

● Case Background: The lawsuit was filed in August 2023 in the U.S. District Court for the Northern District of California, with trial beginning September 8, 2026.

● Not Final: The verdict remains subject to post-trial motions and a possible appeal, meaning the award is not yet a final, collectible judgment.

Nektar Therapeutics (NASDAQ:NKTR) disclosed in an 8-K filed September 25 that a federal jury has found Eli Lilly and Company breached the implied covenant of good faith and fair dealing in the companies' license agreement covering rezpegaldesleukin, awarding Nektar $90 million in damages plus interest to be determined by the court. The verdict, reached September 24, 2026, resolves a trial that began September 8 but remains subject to post-trial motions and a possible appeal.

Background of the Dispute

Nektar said the case, filed in August 2023 in the U.S. District Court for the Northern District of California under docket number 3:23-cv-03943-JD, alleged that Lilly breached both the parties' license agreement directly and the implied covenant of good faith and fair dealing tied to it. That agreement covered rezpegaldesleukin, sometimes called rezpeg, a drug the two companies had been developing and planned to commercialize together under a collaboration arrangement. The 8-K, filed under Item 8.01, Other Events, does not restate the original complaint's specific allegations beyond describing the two causes of action Nektar brought.

What the Jury Decided

After the trial concluded, the jury found in Nektar's favor specifically on the implied-covenant claim, concluding Lilly breached that duty in connection with the license agreement. The jury awarded Nektar $90 million in damages. Nektar said interest on that award will be calculated separately by the court in subsequent proceedings, meaning the final amount Nektar could ultimately collect, if the verdict stands, will exceed the $90 million principal figure once interest is added.

The filing does not indicate whether the jury reached a different or no finding on Nektar's separate breach-of-contract claim, focusing its disclosure on the implied-covenant verdict and damages award. It also does not describe Lilly's defense at trial or summarize any testimony presented by either side.

What Comes Next

Nektar was explicit that the verdict remains subject to post-trial proceedings, and that any resulting judgment could face an appeal. That means the $90 million award, and whatever interest the court eventually determines, is not yet a final, collectible judgment. Post-trial motions in federal cases typically include requests to set aside a verdict or reduce damages, and either outcome, or a subsequent appeal by Lilly, could delay or alter the amount Nektar ultimately receives.

Nektar Therapeutics is a biopharmaceutical company; the filing does not restate its broader pipeline or Business description beyond identifying it as the plaintiff in this litigation against Lilly over their rezpegaldesleukin collaboration. Elizabeth Zhang, Nektar's vice president of legal affairs, signed the 8-K.

What the Filing Does Not Say

The 8-K does not disclose Lilly's response to the verdict, whether Lilly has indicated it will appeal, or a timeline for when post-trial motions might be resolved. It also does not specify the applicable Interest Rate or methodology the court will use to calculate additional interest on the $90 million award, nor does it address the current status of the rezpegaldesleukin collaboration itself following the verdict.

The Path to a Final Judgment

Investors should watch for the resolution of post-trial motions in the Northern District of California case, which could adjust the $90 million damages figure before it becomes final, and for the court's determination of applicable interest. Any notice of appeal filed by Lilly would extend the timeline further before Nektar can expect to collect on the award, and neither company has disclosed next scheduled dates for those proceedings in this filing.